23andMe, FDA and DNA health profiling
Are companies that provide direct-to-consumer information on their personal genome -- including genetic susceptibility to disease -- creating new health risks that need to be regulated? On November 22 2013, the US Food and Drug Administration requested that the personalized DNA analysis company 23a